Here we evaluate the contribution of TLS, B cells and anti-tumour antibodies to immune protection from treatment-naive and immunotherapy-treated LUAD in patients and immunotherapy- and targeted therapy-treated LUAD in a new mouse model3 and uncover an important role for lung-resident B cell responses against ERV envelope glycoproteins. The gene discussed is ERVW-1; the disease is neoplasm.